EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
· Genmab has entered into a definitive agreement to acquire Merus in an all-cash transaction for a total consideration of USD 8.0 billion, making it one of the largest acquisitions of a European biotech company to date · Merus is a clinical-stage oncology company developing bi/tri-specific antibodies, with a pipeline including petosemtamab for head and neck squamous cell carcinoma and other malignancies · EQT Life Sciences has been an investor in Merus since 2010, supporting the Company at board level in its growth from a start-up company to a NASDAQ-listed clinical-stage biotech with